Baidu
map

LCAH:英国青少年感染SARS-CoV-2 3个月后的身心健康(CLOCK)

2022-02-14 从医路漫漫 MedSci原创

我们描述了一组11-17岁、PCR确诊的SARS-CoV-2感染青少年与PCR阴性的匹配青少年的COVID后症状学。

背景:我们描述了一组11-17岁、PCR确诊的SARS-CoV-2感染青少年与PCR阴性的匹配青少年的COVID后症状学。

方法:在这项国家队列研究中,将2021年1月至3月英国公共卫生数据库中SARS-CoV-2检测呈阳性的11-17岁青少年按检测月份、年龄、性别和地理区域与检测阴性的青少年进行配对。测试结束3个月后,对一组青少年进行详细的问卷调查,收集PCR测试时(回顾性)和问卷填写时(前瞻性)的人口学和身心健康资料。我们比较了检测阳性组和检测阴性组之间的症状,并使用潜伏级分析来评估参与者在基线和3个月时的身体症状是否以及如何聚集在一起。

结果:在2021年1月1日至2021年3月31日期间,调查了23048名检测阳性的青少年和27798名检测阴性的青少年,6804名青少年(3065名检测阳性,3739名检测阴性)完成了问卷调查,应答率为13.4%。PCR检测阳性者1084例(35.4%),阴性者309例(8.3%),阳性组936例(30.5%),阴性组231例(6.2%)。检测后3个月,阳性2038例(66.5%),阴性1993例(53.3%),阳性928例(30.3%),阴性603例(16.2%)。检测3个月后,阳性组最常见的症状是疲倦(1196[39.0%])、头痛(710[23.2%])和气短(717[23.4%]),阴性组最常见的症状是疲倦(911[24.4%])、头痛(530[14.2%])和其他(未指明;590[15.8%])。潜伏性分类分析确定了两个分类,其特征是症状少或多。试验阳性组出现多症状的概率估计为29.6%(95%CI为27.4~31.7),阴性组为19.3%(17.7~21.0)(危险度比为1.53;95%CI为1.35~1.70)。多症状类型在PCR结果阳性者多于阴性者,女孩多于男孩,15~17岁青少年高于11~14岁青少年,以及测试前身心健康状况较差的人群中更常见。

表1:完成3个月问卷的所有研究参与者的基线特征

表2:按SARS-CoV-2状态、总体和年龄组分类,检测时报告的症状和检测前的身心健康状况

表3:3个月时按SARS-CoV-2状态报告的症状,总体和按年龄组分层

结论:SARS-CoV-2检测阳性的青少年与检测阴性的青少年有相似的症状,但在PCR检测时和3个月后,单项症状,特别是多项症状的患病率更高。临床医生应该考虑影响功能的多种症状,并识别不同的症状群。多种多样的症状表明,需要多种方式干预,心理和身体健康症状的同时出现,反映了它们之间的密切关系。

原文出处: Stephenson T,  Pinto Pereira SM,  Shafran R, et al.Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study.Lancet Child Adolesc Health 2022 Feb 07

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2037451, encodeId=0f3f203e45135, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 11 20:46:03 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938080, encodeId=12a7193808021, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Mar 20 12:46:03 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321350, encodeId=ac91132135032, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 15 07:46:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193262, encodeId=da1f11932626d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 14 12:21:09 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2037451, encodeId=0f3f203e45135, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 11 20:46:03 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938080, encodeId=12a7193808021, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Mar 20 12:46:03 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321350, encodeId=ac91132135032, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 15 07:46:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193262, encodeId=da1f11932626d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 14 12:21:09 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
    2022-03-20 hukaixun
  3. [GetPortalCommentsPageByObjectIdResponse(id=2037451, encodeId=0f3f203e45135, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 11 20:46:03 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938080, encodeId=12a7193808021, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Mar 20 12:46:03 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321350, encodeId=ac91132135032, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 15 07:46:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193262, encodeId=da1f11932626d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 14 12:21:09 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
    2022-02-15 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2037451, encodeId=0f3f203e45135, content=<a href='/topic/show?id=66f49322993' target=_blank style='color:#2F92EE;'>#身心健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93229, encryptionId=66f49322993, topicName=身心健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Mar 11 20:46:03 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938080, encodeId=12a7193808021, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Mar 20 12:46:03 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321350, encodeId=ac91132135032, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Feb 15 07:46:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193262, encodeId=da1f11932626d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Mon Feb 14 12:21:09 CST 2022, time=2022-02-14, status=1, ipAttribution=)]
    2022-02-14 光明骑士

    0

相关资讯

柳叶刀风湿病学:自身免疫疾病患者SARS-CoV-2血清阳性打新冠疫苗效果竟然更好

对于风湿病患者,新冠疫苗打或者不打,打多少?一直是一个问题。

MOL THER| 妙!科学家发现咀嚼含有ACE2蛋白的口香糖或减少SARS-CoV-2传播

口香糖可能作为这场斗争中的一种额外工具。

NEJM:青少年接种SARS-CoV-2 mRNA-1273疫苗的效果

青少年接种mRNA-1273疫苗具有可接受的安全性。免疫反应与年轻人相似,mRNA-1273疫苗可有效预防Covid-19。

JEADV:脂溢性皮炎与SARS-CoV-2的相关性研究

脂溢性皮炎(SD)是皮炎的一种常见形式。免疫失调被认为在SD的发病机制中起作用,随着年龄增大、免疫抑制和神经精神疾病的患者,SD的患病率增加。

AJH:接受鲁索替尼治疗的骨髓增殖性肿瘤患者对首次 SARS-CoV-2 疫苗接种的反应受损

Covid-19 是由大流行性 SARS-CoV-2 感染引起的疾病,对血液系统疾病患者产生了重大影响。JAK1 和 JAK2 抑制剂 (JAKi) ruxolitinib 被批准用于治疗 MF 和羟

Baidu
map
Baidu
map
Baidu
map